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Background: There is growing evidence that emerging malignancies in solid tissues might be kept under control
by physical intercellular contacts with normal fibroblasts.
Methods: Here we characterize transcriptional landscapes of fibroblasts that confronted cancer cells. We studied
four pairs of in vitro and ex vivo fibroblast lines which, within each pair, differed in their capacity to inhibit cancer
cells. The natural process was modeled in vitro by confronting the fibroblasts with PC-3 cancer cells. Fibroblast
transcriptomes were recorded by Affymetrix microarrays and then investigated using network analysis.
Results: The network enrichment analysis allowed us to separate confrontation- and inhibition-specific components
of the fibroblast transcriptional response. Confrontation-specific differences were stronger and were characterized
by changes in a number of pathways, including Rho, the YAP/TAZ cascade, NF-kB, and TGF-beta signaling, as well
as the transcription factor RELA. Inhibition-specific differences were more subtle and characterized by involvement
of Rho signaling at the pathway level and by potential individual regulators such as IL6, MAPK8, MAP2K4, PRKCA,
JUN, STAT3, and STAT5A.
Conclusions: We investigated the interaction between cancer cells and fibroblasts in order to shed light on the
potential mechanisms and explain the differential inhibitory capacity of the latter, which enabled both a holistic
view on the process and details at the gene/protein level. The combination of our methods pointed to proteins,
such as members of the Rho pathway, pro-inflammatory signature and the YAP1/TAZ cascade, that warrant further
investigation via tools of experimental perturbation. We also demonstrated functional congruence between the
in vitro and ex vivo models.
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Stoker et al. have shown that normal fibroblasts can inhibit
the growth of cancer cells in vitro [1] and termed this effect
as neighbor suppression. Recently, our group has confirmed
this finding in a high-throughput system [2, 3] and showed
that fibroblasts from puncture biopsies, taken from patients
with prostatic cancer, had less inhibitory effect than normal
skin fibroblasts. In normal tissues, the inhibitory effect dif-
fered depending on the original location of the fibroblasts.
Hernia fibroblasts were less inhibitory than skin fibroblasts.
Flaberg et al. [3] also showed that fibroblasts differing in
their ability to inhibit tumor growth and motility can be
isolated from the telomerase immortalized foreskin fibro-
blast line, BJ/TERT on the basis of their morphology. The
more inhibitory sublines were designated as whirly (Wh),
the less inhibitory as crossy (Cr). In this paper these two
lines will be referred to as “in vitro” cells, whereas 6 other
lines derived from recent biopsies will be referred to as
“ex vivo“cells.
It is known that the normal tumor inhibitory microenvir-
onment becomes “corrupted” during tumor development.
This is reflected by appearance of a large and heteroge-
neous category of cancer-associated fibroblasts (CAFs) that
fail to inhibit tumor growth or actually stimulate it. The
molecular basis of this functional difference is not known.
CAFs were shown to express markers associated with
wound healing [4], inflammation [5], and epithelial-
mesenchymal transition [6]. In an in situ analysis of
antibody-stained tumor images from the Human Protein
Atlas we have identified 12 new CAF markers expressed in
cancer stroma but not in normal fibroblasts [7]. In the most
recent work we studied protein factors that might be
closely responsible for the cancer cell-fibroblast interaction
and could distinguish between extracellular matrix based
and soluble ones [8].
In order to examine the role of major genes and path-
ways that shape the CAF-tumor interaction and influence
the tumor inhibitory capacity of fibroblasts, the 2 in vitro
and 6 ex vivo fibroblasts were co-cultivated with a prostate
cancer cell line in vitro. Transcriptome profiling of fibro-
blast cells was performed with Affymetrix microarrays.
The present study aimed at:
i. Characterizing the transcriptome response of the
eight fibroblast lines to tumor cells in the course of
in vitro co-culturing “confrontation experiment”;
ii. Determining the transcriptional correlates of
differential inhibition capacity;
iii. Examining the prognostic and, potentially,
treatment-relevant significance of the genes
highlighted by the steps (i) and (ii) above, by
utilizing public resources of clinical and molecular
(gene expression) data from The Cancer Genome
Atlas [9].Global analysis of transcription usually generates long
lists of differentially expressed (DEG) genes. Their com-
mon features can be revealed by gene set enrichment
analysis (GSEA) against functionally annotated gene sets,
such as Gene Ontology terms [10] or KEGG pathways
[11] that significantly overlap with lists of DEGs are then
used to characterize the latter. Known drawbacks of
GSEA are that 1) most of the genes do not have specific
annotations in the databases, 2) the overlap can only be
observed for genes that differ transcriptionally in the
relevant comparisons, which omits proteins that func-
tion via other mechanisms, e.g. by phosphorylation, and
3) the statistical power of the analysis is limited by the
sizes of functional gene sets (FGS). The smaller a gene
set, the harder is it to prove its significance in GSEA –
whereas a deeper study would usually focus on compact
pathways. As an example from Reactome database [12],
the “mitotic cell cycle” pathway consisted of 329 genes,
whereas only 121 and 43 of these genes constituted “cell
cycle checkpoints” and “G2-M checkpoint”, respectively.
The latter two are much more difficult to identify in
GSEA.
In order to overcome these limitations, we recently ex-
tended GSEA to network enrichment analysis (NEA)
[13]. The key difference is that GSEA calculates the sig-
nificance of overlap of member genes between DEGS
and a functional gene set, whereas the significance in
NEA is evaluated by functional connections (network
links) that have been identified between genes of the two
groups. The source of functional connections for NEA is
a global network of functional coupling between genes
and proteins, such as FunCoup [14, 15].
This generalization allows NEA to circumvent the above
mentioned drawbacks of GSEA by considering nearly all
known genes and proteins and their molecular modi
operandi. As demonstrated in [13], the statistical power of
NEA is an order of magnitude higher compared to GSEA.
In addition, the method can analyze individual DEGs and
key functional regulators against gene sets. These features
were indispensable in the context of the present work, since
we were looking for fine-grained mechanisms shaped by a
few DEGs and small pathways. In particular, when the list
of binding sites predicted for transcription factors was pre-
sented as a set of network edges, the NEA methodology
permitted the identification of binding sites enriched in lists
of DEGs. NEA can also demonstrate that different DEGs,
when combined in a top-ranking list, relate to each other.
Special statistical tests rejected the null hypothesis that the
list members merely represented random sets of genes,
which thus indicated their functional coherence (i.e. ap-
pearance as a network module).
In this article, we investigated the expression of genes in
fibroblasts that differed in their cancer inhibitory capacity.
Observations were made before and after fibroblast
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fibroblast transcriptomes were analyzed by NEA, both for
their individual and collective properties. We also tested
the prognostic significance of the identified key genes in
ten different cancers. Our overall aim was to generate bio-
logical hypotheses for further experimental testing and to
suggest genes that would warrant further investigation.
Methods
Primary human fibroblasts
Primary human fibroblasts were cultivated from diagnostic
biopsy samples or from surgically removed tissue pieces
from different anatomic locations of pediatric and adult
patients. Primary skin fibroblasts were isolated from a
pediatric patient wound site skin (dubbed as pediatric skin
fibroblast PdSFB). From the same pediatric patient, fibro-
blasts were also obtained by resection during umbilical her-
nia surgery (pediatric hernia fibroblast PdHFB). Fibroblasts
HS68, derived from skin of a healthy donor (available in
ATCC), were provided by Prof. Kenneth Wu (NHRI,
Taiwan).
Fibroblasts PrNFB1 (prostate normal fibroblast 1),
PrTFB1 (prostate tumor fibroblast 1) and PrTFB2 (pros-
tate tumor fibroblast 2) were derived from the following
prostate biopsies:
 PrNFB1 from a non-tumor (normal) prostate area in
a patient with prostate carcinoma,
 PrTFB1 from a tumor area of the same patient, and
 PrTFB2 from a tumor prostate area in another
patient with prostate carcinoma.
These primary human prostate fibroblast cultures were
established using the method by Tuxhorn et al. [16] as
previously described. In brief, fresh prostate tissue de-
rived from radical prostatectomy was diced in small
pieces of about one mm3. These pieces were put into 6-
well tissue culture plates and were fixed in the well
under a cover slide. Then 1.5 ml Bfs medium [DMEM
(Hyclone) supplemented with 5 % FBS (Hyclone), 5 %
Nu Serum (BD Biosciences), 5 mg/ml Insulin, 0.5 μg/ml
Testosterone, 4 mM L-glutamine and 1× Penicillin/
Streptomycin (all from Sigma)] was added to each well,
and the tissue pieces were incubated at 37 °C with 5 %
CO2. Fibroblast-like cells started to migrate out from
the tissue between 5 and 15 days and were passaged
when confluent. The fibroblast nature of the tissue-
derived cell cultures was verified by their fibroblast-
characteristic morphology and the expression of fibroblast-
markers such as PDGFR-beta, alpha-SMA, but not e.g.
e-cadherin [8].
After generation of primary fibroblasts, they were cul-
tured in IMDM supplemented with 20 % FBS and antibi-
otics. Primary fibroblasts of passage number below elevenwere used in the tumor/fibroblast co-culture assays. All
primary fibroblasts were additionally transduced with GFP
(the green fluorescent protein) using third generation
lentivirus produced in our facilities. The lentivirus vectors
were generous gift from Prof. Galina Selivanova (Karolinska
Institute).
Ethical permissions
The primary fibroblasts were obtained from surgical or
diagnostic rest material. Informed consent from either pa-
tients or parents was received. All samples were coded and
only information about age, gender and site of origin were
given to investigators. The handling of these materials was
approved both by the Regional and Institutional Ethics
Committee, University of Debrecen Medical and Health
Science Center (DEOEC RKEB/IKEB no. 2918–2009) (for
the PdSFB and PdHFB fibroblasts) and the Regional Ethical
Review Board in Stockholm (No. 2010–087).
Isolation of subclones of BjhTERT fibroblasts
The maintenance of the human fibroblasts that were im-
mortalized with the catalytic subunit of human telomerase
(hTERT), BjhTERT, and the isolation of their subclones
have been described previously [3]. Namely, we obtained
the sub-clones by plating 1000 BjhTERT cells in a 10-cm
tissue-culture dish in 10 ml Iscove’s modified Dulbecco’s
medium containing 10 % fetal bovine serum, 100 μg/ml of
penicillin/streptomycin. A few colonies started to appear
after 2 to 3 weeks. After 4 weeks, the colonies were exam-
ined under light microscopy, and 48 colonies were re-
moved from the dish using a pipette tip, and were
cultured further. Out of these 48 subclones, we selected
two that showed the ‘whirly’ (Wh1) and ‘crossy’ (Cr9) phe-
notypes. These whirly and crossy fibroblasts then main-
tained their phenotypic differences during serial passages.
Co-culture inhibition assay
Tumor cell proliferation on fibroblast monolayers was an-
alyzed in 384-well plates. Fibroblasts were plated in 80 μl
complete medium and cultured for 5–6 days to form con-
fluent and aged monolayers. H2AmRFP labeled PC-3
tumor cells were plated in fresh 80 μl complete medium
on top of the fibroblast monolayers. The control wells
contained 200 labeled tumor cells without fibroblasts. The
inhibition score was calculated, as explained in details in
[8], by dividing the number of tumor cells on day 5 with
the number of tumor cells on day 0.
Automated microscopy
Every well of the 384-well plate was imaged using a modi-
fied version of the automated microscope system. We
used the Openlab automation Platefocus 10, developed by
us. Images at 2.5× magnification (NA 0.08), covering the
entire bottom-area of a well, were captured after seeding
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with fibroblasts. At each time-point both transmitted light
and fluorescence images were captured (excitation at
560 nm and emission at 600–620 nm for mRFP labeled
cancer cells). The microscope platform was built using a
Nikon microscope (Nikon, Tokyo, Japan), a programmable
XY-table (Märzhauser, Germany) and a Retiga-4000RV
(QImaging, Surrey, BC, Canada). Using binning 2, raw im-
ages were 1024 × 1024 pixels in size. The system was run
on a Mac OS X, version 10.5.6, processor 2 × 3 GHz
Quad-Core Intel Xeon.Affymetrix microarrays
Co-cultures were started by plating 0,5 × 106 fibroblasts in
collagen coated 10 cm dishes for 5–7 days. When cells
reached full-confluency and the monolayers were ma-
tured, cells were washed 3× with PBS and 0,5 × 106 PC-3
mRFP tumor cells were added for 4 days in complete
medium. After 4 days of co-culture, the cells were washed
3× with PBS, trypsinized, and then the fibroblasts were
sorted using BD FACSVantage (CA, USA). Total RNA
was purified from flow cytometry sorted fibroblasts with
and without PC-3 mRFP confrontation using the RNA
Purification Kit (Ambion, USA) according to the manufac-
turer’s instructions. The Affymetrix Gene Chip WT Sense
Target Labeling and Control Reagents kit (P/N 900652)
was used for preparation of cDNA from 150 ng of total
RNA. Array hybridization, washing, staining and scanning
were performed on the Gene Titan system using the Gene
Chip Human Gene 1.1 ST Array plate. Combining the
probes, normalization and background correction were
performed in Affymetrix Expression Console (v. 1.3.1)
using the RMA method.
The data are available at Gene Expression Omnibus under
Accession number GSE57199: https://www.ncbi.nlm.nih.-
gov/geo/query/acc.cgi?acc=GSE57199.Differential expression analysis
We detected differential expression between conditions of
interest with R package OCplus [17]. This program en-
ables fast calculation of both paired (which was applied
when relevant) and independent t-tests across individual
genes. Log2-tranformed values of the microarray dataset
were normally distributed. We considered only genes with
assigned HUGO symbol (by Affymetrix probe annotation).
After visual investigation of the mean vs. variance plot, we
detected a larger cluster of genes that stood out by low
variance and low mean expression value across all the 16
samples. According to this observation, around 9000
genes with variance <0.1 and mean <4 were removed as
likely “absent”. After this filtering, any correlation between
mean and variance disappeared, which constituted a re-
quirement for the t-test. The t-statistics were transformedto p-values and then adjusted for multiple testing using
the procedure by Benjamini and Hochberg [18].
Functional gene sets (FGS)
A larger compendium of pathways, such as KEGG, Reac-
tome, BioCarta, WikiPathways, and otherwise defined func-
tional sets (e.g. gene signatures) was downloaded from
http://www.broadinstitute.org/gsea/msigdb/index.jsp as of
April, 2011.
It was complemented with GO terms not larger than
500 genes, and custom gene sets compiled by us from
literature. As the total size of this collection was more
than 3000 sets, we then filtered it down to 82 pathways,
which seemed to be the most relevant to this study.
Global interaction network
The FunCoup network [14] integrated evidence of func-
tional links using public data from multiple sources, high-
throughput gene and protein expression profiling,
sequence analysis (promoter and miRNA binding) and ex-
perimental evidence and annotations (physical contacts
between proteins, sub-cellular co-localization etc.). We
previously published results of a network benchmark [15]
where we tested different combinations of known and pre-
dicted global networks by their ability to recover known
members of functional gene sets. Here we use the best
network version which was obtained by merging FunCoup
edges at confidence higher than 0.5 with all known edges
from the curated databases KEGG [11], PhosphoSite [19],
CORUM [20], MSigDB [21], and HTRIdb [22]. The result-
ing union network had 974,427 functional links between
19,031 distinct HUGO gene symbols. Since these informa-
tion sources could be either gene-, transcript-, or protein-
specific and cover a wide range of cellular mechanisms
and data mining approaches, the edges in the network
represent unspecified “functional couplings” between
nodes which could be both genes and proteins (referred to
via HUGO gene symbols).
Network enrichment analysis
We probabilistically estimated putative functional rela-
tions between pre-specified gene sets with the network
enrichment analysis (NEA), a method presented earlier
by Alexeyenko et al. [11, 22].
The standard z-score for the biological network con-
nectivity between genes of a novel list (altered gene set,
AGS) and genes of a known functional gene set (FGS,
most commonly a pathway or a Gene Ontology term)
could be quantified as a total number of links (edges)
known in the global interaction network that connect any
genes of AGS to any genes of FGS [13]. In the current
work, we used a formula to calculate the number of links
between AGS and FGS expected by chance:
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nð AGS‐FGS−n^AGS‐FGSÞ2
n^AGS‐FGS
þ

!nð AGS‐FGS−!n^AGS‐FGSÞ2
!n^AGS‐FGS
;
where nAGS-FGS is the actual number of links between any
genes of AGS and any genes of FGS, the respective number
of links expected by chance is n^AGS‐FGS ¼ NAGSNFGS2Ntotal , and !n
denotes “other than n”.
NAGS and NFGS report the sums of connectivities of in-
dividual nodes (genes) in AGS and FGS, respectively,
while Ntotal is the number of edges in the whole
network.
The statistic used cumulative connectivity values (total
number of network links of all genes in the whole network)
and was unbiased even if AGS and/or FGS are small and/
or the network is sparse. Deviation of the actual value nAGS-
FGS from the observed one followed the chi-squared distri-
bution and was not biased due to small n (Alexeyenko et al.
[23] and unpublished results). In addition, this procedure
was fast since multiple rounds of network randomization
were not required – as compared to the algorithm earlier
proposed by Maslov and Sneppen [24] and later imple-
mented by us [13]. Of note, this simplification was only ap-
plicable when quantifying direct links nAGS-FGS. Evaluating
any other, more complicated network pattern would war-
rant network randomization. The values were transformed
to p-values and then adjusted for multiple testing [18]. We
considered relations between AGS and FGS as significant
when FDR <0.1, supported by at least 5 links.
We performed NEA with our software NEA.pl which
was described in Merid et al. [15] and is available at http://
research.scilifelab.se/andrej_alexeyenko/downloads.html. As
a complement to the procedures described above, it per-
formed binomial Gene Set Enrichment Analysis (GSEA)
between the same gene sets, and reported the number of
shared member genes.
In addition to group-wise AGS-FGS relations, NEA
could analyze relations in a mode referred to as “single
gene vs. AGS”, i.e. when a single gene was taken as if it
were a pathway. Thus, the FGS was presented with a sin-
gle gene, while the calculation otherwise was identical to
[2]. This more specific mode facilitated the identification
of both known pathway members and genes not assigned
to any pathways. Of note, this is not possible in Gene Set
Enrichment Analysis (GSEA).
Simultaneous analysis of binding site enrichment and
correlation of gene expression
We used the database of high-confidence predicted and
experimental transcriptional factors (TF) and their tar-
gets HTRIdb [22] to analyze potential transcriptional
regulators of the DE lists. We identified TFs most sig-
nificantly linked to DE lists with our NEA software. In
order to validate relevance of HTRIdb in this context, welooked at individual correlations in our expression datasets
between profiles of identified TFs and respective DEGs
across the 16 samples. After adjustment for expression pro-
file length and multiple testing, we saw about 9-fold excess
of correlated (FDR < 0.05) TF-target pairs compared to the
pattern expected by chance (Additional file 1: Figure S5).
Of note, here “by chance” implies presence of some non-
zero fraction of correlated gene pairs, since many TFs
would have global, unspecific effects. Hence taking into ac-
count existence of this truly regulation in certain random
pairs, the formal level of FDR was close the empirical
estimate.
Results
General design of the experiment
The fibroblasts were co-cultured with PC-3 cells. Their
effect was quantified by scoring the number of cancer
cells in each Petri dish after 72 h. The transcriptional
consequences were evaluated in eight fibroblast lines in-
cluding two sub-clones of the immortalized BjhTERT
line Wh1 and Cr9 that differed in their capacity to in-
hibit cancer cells and six ex vivo fibroblast cell cultures
that were sampled from either tumors or healthy tissues.
The fibroblasts were harvested for mRNA expression
analysis with and without PC-3 co-culture. All fibro-
blasts were confronted with tumor cells under the same
conditions, and the experimental design included two
points for each of the eight samples. Differential expres-
sion was detected for each gene on the chip in a number
of statistical tests, namely by contrasting 1) the pre- ver-
sus post-confrontation transcriptomes and 2) by taking
into account differences in inhibitory capacity of the dif-
ferent fibroblast samples. In addition, we were able to
compare the in vitro and the ex vivo cell lines to deter-
mine their relevance as models of confrontation and
inhibition.
For an overview of the transcriptional changes during
the confrontation of fibroblasts with PC-3 cancer cells, we
performed the principal component analysis (PCA) of the
fold change values on all genes in each of the eight sam-
ples. Fig. 1 shows that the samples distributed relatively
evenly in the space of the first four principal components.
Together, the four principal components took into ac-
count more than 87 % of total fold change variance. It is
important to note that this analysis gave the most general
view of the transcriptional landscape, where the most in-
fluential genes were those most different across all the 16
samples. In the following analysis, we will focus on more
specific features, related to the confrontation with tumor
cells and the capacity to inhibit the latter. Due to the com-
mon origin, the two in vitro samples Wh1 and Cr9 occu-
pied close positions in each of the four PCA dimensions.
However with the exception of component 3, they do not
appear as an extreme group compared to the six ex vivo
Fig. 1 Overview of the transcriptional change during the confrontation with tumor cells in the eight fibroblast samples. The principal component
(PC) analysis was performed of log2-transformed fold change expression values from Affymetrix for each gene in each of the 16 samples The text
labels refer to cell sample IDs (see Methods) and are centered at the respective coordinates without offset. PCs from 1 to 4 are plotted as X and Y
axes pair-wise. These four components took into account 49.9, 19.2, 11.2, and 7.4 % of the fold change variance, respectively. The analysis was
meant to identify if any samples stand out compared to others in terms of overall expression
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of the post-confrontation samples (namely those with Wh1,
Cr9, and PdSFB) might contain relatively high amounts of
tumor cells, and thus introduced a potential bias compared
to the non-contaminated cells. However when compared to
the rest of the samples, they did not stand out in any of the
plotted components. From this we concluded that the can-
cer cell contamination was unlikely to have a larger impact
on the analysis compared to other factors that determined
variability between the samples.Confrontation with tumor cells
The confrontation of fibroblasts with PC-3 cells con-
tinuously for 72 h had a profound influence on the tran-
scriptomes of the fibroblast lines, irrespectively of their
inhibitory capacity. This warranted detailed functional
investigation of differentially expressed genes (DEGs).
The comparison of confronted vs. non-confronted
fibroblasts across all the eight cell lines yielded an
extensive list of 867 DEGs with a false discovery rate
(q-value) < 0.05.Applying the network enrichment analysis (NEA), we
tested three DEG lists of different stringency: top 30, top
100, and top 300 genes that were most affected by the
72-h confrontation (as indicated above, the full list of
significantly changing DEGs was much longer). Since
the three lists gave comparable results that differed only
by statistical power to detect pathways of known rele-
vance, in the following we only report the analysis on
the top 300 DEGs.
Multiple signaling pathways were enriched in network
links to the DEGs, such as WNT, JAK-STAT, VEGF, apop-
tosis, insulin signaling, and others (Fig. 2). This was an im-
portant but not exclusive feature of the confrontation.
Nearly all the same pathways were also identified in relation
to inhibitory capacity (see next section). In the confronta-
tion experiment, many pathways could share influential
genes that contributed to enrichment, and the pathway
scores could thereby positively correlate to each other. For
example, NFKB1 was a member of three Reactome path-
ways related to NF-kB and each of the latter were enriched
in our analysis (Additional file 2: File S1). Their member
genes produced altogether 105, 90, and 74 individual links
Fig. 2 Network enrichment of experimentally perturbed genes. The summary of gene set (DEG vs. pathways or TFs) connections in the global network was
performed using NEA. For description of the computational procedure see “Network enrichment analysis” in Methods. Lists of DE genes characterized either
1) expression change in the course of confrontation with tumor cells or 2) differential inhibition capacity of fibroblasts in regard of tumor cells. Red: lists of
differentially expressed genes (DEG) from our experiment. Green: annotated pathways from public resources enriched in connections to DEGs. Yellow:
individual transcription factors (TF) selected for their enrichment in network connections to DEGs. Lines are NEA-based summaries of individual, gene-gene
network edges that connect DEGs and pathways between which significant network enrichment was detected (minimal NEA FDR< 0.01 and number of
individual gene-gene links (see edge labels) at least 10 per pathway and at least 3 per TF). The image was created using software Cytoscape [39]
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However, NFKB1 itself would be responsible for regulating
not more than 19 out of 300 DEGs. To reveal both core
pathway members like NFKB1 and other potential genes
that might not have been assigned to any pathway, we re-
trieved network nodes that were most significantly linked
to DEGs in the “single gene vs. DEG list” mode of NEA
(see Methods). Using this approach, we identified a number
of transcription factors (FOXO1, FOXO2, FOXO3,
FOXO4, FOXP3, GATA1, GATA2, GATA4, SOX9, HSF2,
SMAD3) and other potential regulators of the confronta-
tional response (Table 1).
Four cadherin-related pathways available in our collec-
tion were significantly associated with the confrontational
response (NEA FDR < 10−19 for each of the pathways). In
particular, we found that CAMK2A (calcium/calmodulin-
dependent protein kinase II delta) was likely to be con-
trolled by two transcription factors. The promoter regionfor CAMK2A contained binding sites for the transcription
factors RORA and REL. RORA and REL were differen-
tially expressed during the confrontation and their expres-
sion patterns were significantly correlated during that
process (Pearson r = 0.777, p0 = 0.00018; Fig. 3) across the
samples. Importantly, our network enrichment analysis
was able to summarize bi-directional relations between
DEGs and pathways. For example, we established, in a
similar manner as above, that RORA could regulate two
members of the KEGG pathway “Cytokine-cytokine re-
ceptor interaction”: colony stimulating factor CSF3 and
CD40LG (the CD40 ligand). The latter genes were not in-
cluded in the DEG list, because of lower significance of
differential expression, but their expression pattern was
still highly correlated with RORA expression.
We also found specific involvement of Rho signaling in
the confrontational change. The transcription factor RELA,
a co-factor of NFKB1, was likely to regulate a number of
Table 1 Genes with potentially broad impact on the confrontation and the inhibitory capacity
Gene Method of
prioritization
Role Description
NFKBIA Confrontation DEG Co-regulated by RELA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha [Source: HGNC Symbol;
Acc:7797]
IL1B Confrontation DEG Co-regulated by RELA interleukin 1, beta [Source: HGNC Symbol; Acc:5992]
RELT Confrontation DEG Co-regulated by RELA RELT tumor necrosis factor receptor [Source: HGNC Symbol; Acc:13764]
BHLHE40 Confrontation DEG Co-regulated by RELA basic helix-loop-helix family, member e40 [Source: HGNC Symbol; Acc:1046]
FOS Connected to confrontation
DEGs
Transcription factor FBJ murine osteosarcoma viral oncogene homolog [Source: HGNC Symbol; Acc:3796]
SRF Connected to confrontation
DEGs
Transcription factor serum response factor (c-fos serum response element-binding transcription factor) [Source: HGNC Symbol;
Acc:11291]
FOSB Confrontation DEG Co-regulated by RELA FBJ murine osteosarcoma viral oncogene homolog B [Source: HGNC Symbol; Acc:3797]
CYR61 Connected to confrontation
DEGs
Pro-inflammatory signature (Erez et al., 2012) cysteine-rich, angiogenic inducer, 61 [Source: HGNC Symbol; Acc:2654]
IKBKB Connected to confrontation
DEGs
Pro-inflammatory signature (Erez et al., 2012) inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta [Source: HGNC Symbol; Acc:5960]
IKBKE Connected to confrontation
DEGs
Pro-inflammatory signature (Erez et al., 2012) inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon [Source: HGNC Symbol; Acc:14552]
IKBKG Connected to confrontation
DEGs
Pro-inflammatory signature (Erez et al., 2012) inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma [Source: HGNC Symbol; Acc:5961]
IKBKG Connected to confrontation
DEGs
Pro-inflammatory signature (Erez et al., 2012) Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma, isoform CRA_b [Source: Uni-
ProtKB/TrEMBL; Acc:D3DWY0]
NR4A2 Connected to confrontation
DEGs
Pro-inflammatory signature (Erez et al., 2012) nuclear receptor subfamily 4, group A, member 2 [Source: HGNC Symbol; Acc:7981]
PDGFRA Connected to confrontation
DEGs
Pro-inflammatory signature (Erez et al., 2012) platelet-derived growth factor receptor, alpha polypeptide [Source: HGNC Symbol; Acc:8803]
ANXA4 inhibition DEG Co-regulated by FOXA1 annexin A4 [Source: HGNC Symbol; Acc:542]
CDK6 inhibition DEG Co-regulated by FOXA1 cyclin-dependent kinase 6 [Source: HGNC Symbol; Acc:1777]
KAZN inhibition DEG Co-regulated by FOXA1 kazrin, periplakin interacting protein [Source: HGNC Symbol; Acc:29173]
RMND5A inhibition DEG Co-regulated by FOXA1 required for meiotic nuclear division 5 homolog A (S. cerevisiae) [Source: HGNC Symbol; Acc:25850]
TNS3 inhibition DEG Co-regulated by FOXA1 tensin 3 [Source: HGNC Symbol; Acc:21616]
IL6 Connected to inhibition
DEGs
Potential regulator interleukin 6 (interferon, beta 2) [Source: HGNC Symbol; Acc:6018]
MAPK8 Connected to inhibition
DEGs
Potential regulator mitogen-activated protein kinase 8 [Source: HGNC Symbol; Acc:6881]
MAP2K4 Connected to inhibition
DEGs
Potential regulator mitogen-activated protein kinase kinase 4 [Source: HGNC Symbol; Acc:6844]
PRKCA Connected to inhibition
DEGs
Potential regulator protein kinase C, alpha [Source: HGNC Symbol; Acc:9393]
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Table 1 Genes with potentially broad impact on the confrontation and the inhibitory capacity (Continued)
YBX1 Connected to inhibition
DEGs
Transcription factor Y box binding protein 1 [Source: HGNC Symbol; Acc:8014]
GFI1 Connected to inhibition
DEGs
Transcription factor growth factor independent 1 transcription repressor [Source: HGNC Symbol; Acc:4237]
ESR1 Connected to inhibition
DEGs
Transcription factor estrogen receptor 1 [Source: HGNC Symbol; Acc:3467]
ETS1 Connected to inhibition
DEGs
Transcription factor v-ets avian erythroblastosis virus E26 oncogene homolog 1 [Source: HGNC Symbol; Acc:3488]
ETS2 Connected to inhibition
DEGs
Transcription factor v-ets avian erythroblastosis virus E26 oncogene homolog 2 [Source: HGNC Symbol; Acc:3489]
AR Connected to inhibition
DEGs
Transcription factor androgen receptor [Source: HGNC Symbol; Acc:644]
GATA1 Connected to inhibition
DEGs
Transcription fact or GATA binding protein 1 (globin transcription factor 1) [Source: HGNC Symbol; Acc:4170]
GATA2 Connected to inhibition
DEGs
Transcription factor GATA binding protein 2 [Source: HGNC Symbol; Acc:4171]
GATA3 Connected to inhibition
DEGs
Transcription factor GATA binding protein 3 [Source: HGNC Symbol; Acc:4172]
PAX2 Connected to inhibition
DEGs
Transcription factor paired box 2 [Source: HGNC Symbol; Acc:8616]
JUN Connected to inhibition
DEGs
Transcription factor jun proto-oncogene [Source: HGNC Symbol; Acc:6204]
STAT3 Connected to inhibition
DEGs
Transcription factor signal transducer and activator of transcription 3 (acute-phase response factor) [Source: HGNC Symbol;
Acc:11364]
STAT5A Connected to inhibition
DEGs
Transcription factor signal transducer and activator of transcription 5A [Source: HGNC Symbol; Acc:11366]
CAMK2A Confrontation DEG Involved in TGFbeta signaling, associated
with survival
calcium/calmodulin-dependent protein kinase II alpha [Source: HGNC Symbol; Acc:1460]
CDK6 Confrontation DEG Involved in TGFbeta signaling, associated
with survival
cyclin-dependent kinase 6 [Source: HGNC Symbol; Acc:1777]
CDKN2B Confrontation DEG Involved in TGFbeta signaling, associated
with survival
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) [Source: HGNC Symbol; Acc:1788]
NR4A1 Confrontation DEG Involved in TGFbeta signiling, associated
with survival
nuclear receptor subfamily 4, group A, member 1 [Source: HGNC Symbol; Acc:7980]
SMAD3 Confrontation DEG Involved in TGFbeta signiling, associated
with survival
SMAD family member 3 [Source: HGNC Symbol; Acc:6769]
TGFB1 Confrontation DEG Involved in TGFbeta signiling, associated
with survival
transforming growth factor, beta 1 [Source: HGNC Symbol; Acc:11766]
TGFB3 Confrontation DEG Involved in TGFbeta signiling, associated
with survival
transforming growth factor, beta 3 [Source: HGNC Symbol; Acc:11769]
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Table 1 Genes with potentially broad impact on the confrontation and the inhibitory capacity (Continued)
EFNB2 inhibition DEG Associated with survival ephrin-B2 [Source: HGNC Symbol; Acc:3227]
TMEM220 inhibition DEG Associated with survival transmembrane protein 220 [Source: HGNC Symbol; Acc:33757]
TFAP2C inhibition DEG Associated with survival transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma) [Source: HGNC Symbol;
Acc:11744]
RPSAP52 inhibition DEG Associated with survival ribosomal protein SA pseudogene 52 [Source: HGNC Symbol; Acc:35752]
SLC40A1 inhibition DEG Associated with survival solute carrier family 40 (iron-regulated transporter), member 1 [Source: HGNC Symbol; Acc:10909]
CYP1B1 inhibition DEG Associated with survival cytochrome P450, family 1, subfamily B, polypeptide 1 [Source: HGNC Symbol; Acc:2597]
CHAC1 inhibition DEG Associated with survival ChaC, cation transport regulator homolog 1 (E. coli) [Source: HGNC Symbol; Acc:28680]
CCL2 inhibition DEG Associated with survival chemokine (C-C motif) ligand 2 [Source: HGNC Symbol; Acc:10618]
PSAT1 inhibition DEG Associated with survival phosphoserine aminotransferase 1 [Source: HGNC Symbol; Acc:19129]
RCAN2 inhibition DEG Associated with survival regulator of calcineurin 2 [Source: HGNC Symbol; Acc:3041]
SCG2 inhibition DEG Associated with survival secretogranin II [Source: HGNC Symbol; Acc:10575]
AEBP1 inhibition DEG Associated with survival AE binding protein 1 [Source: HGNC Symbol; Acc:303]
MXRA8 inhibition DEG Associated with survival matrix-remodelling associated 8 [Source: HGNC Symbol; Acc:7542]
TBC1D1 inhibition DEG Associated with survival TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 [Source: HGNC Symbol; Acc:11578]
ITGA6 inhibition DEG Associated with survival integrin, alpha 6 [Source: HGNC Symbol; Acc:6142]
PLAUR inhibition DEG Associated with survival plasminogen activator, urokinase receptor [Source: HGNC Symbol; Acc:9053]
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Fig. 3 Expression patterns of transcription factors and their likely targets as related to confrontation with tumor cells. The plots are using log2-transformed
expression values from Affymetrix. The text labels refer to cell sample IDs (see Methods) and are centered at the respective coordinates without offset.
Green: gene expression before confrontation with tumor cells; Red: gene expression after 72 h of confrontation
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analysis of binding sites and gene expression, one member
of Rho signaling, the neuroepithelial cell transforming
factor, NET1, appeared the most likely target of RELA
(Additional file 1: Figure S1). Based on the same analysis,
we concluded that RELA could also regulate the NF-kB
inhibitor, NFKBIA, the interleukin IL1B, the TNF receptor
RELT, and BHLHE40, which was one of the 12 CAF
markers identified in silico [7]. Otherwise, regulation
through Rho signaling could be implemented via the tran-
scription factors (TF) FOS and SRF, which had predicted
binding sites in 8 and 44 DEGs, respectively (NEA FDR
<0.01 for each relation). However, Rho-signaling is not
limited to these two TFs. The whole enrichment pattern of
DEGs towards these pathways involved tens of genes and
hundreds of functional links (Additional file 2: File S1).
We noticed that while binding sites for a number of
transcription factors were enriched against the DEG list as
a whole on the one hand, a subset of these factors, such as
AR, MYB, ETS1, EGR1, GATA2, RELA and RREB1 may
all target the same gene FOSB (FBJ murine osteosarcoma
viral oncogene homolog) on the other hand. In particular,
binding sites for RELA were identified in the FOSB pro-
moter, while expression patterns of these two genes corre-
lated significantly (Additional file 1: Figure S1).
Aragona et al. [25] pointed to a mechanical checkpoint of
multicellular growth that acts via two transcriptional co-
activators: the yes-associated protein YAP1 and tafazzin
TAZ. The checkpoint mechanism continues downstream
towards the Hippo pathway [26]. Indeed, we found (Fig. 4a)
that two genes of the YAP/TAZ cascade (cysteine-rich an-
giogenic inducer 61, CYR61 and connective tissue growth
factor, CTGF, a.k.a. hypertrophic chondrocyte-specific pro-
tein 24) were intertwined in the network of the Hippo
pathway-related genes, MOB3C and TEAD3, and were also
connected with proteins of the pro-inflammatory signature
[27] interleukin IL1B, kinases IKBKB, IKBKE, IKBKG,
nuclear receptors NR4A2 and NR4A2, PDGF receptorPDGFRA, and serglycin SRGN, as well as with tens of genes
of the confrontation-specific DEG list including NFKB1,
REL, and CASP1 (labeled red on Fig. 4a). This sub-network
also displayed the involvement of TGF-beta signaling. Re-
cently, Busch et al. [28] found that expression of TGFBR2
in CAFs of breast carcinoma could be associated with over-
all survival. In our analysis using The Cancer Genome Atlas
data (reported in details below), TGFBR2 was associated
with survival in ovarian and renal carcinoma. In addition,
we identified associations between survival and expression
of CDKN2B, BMP2, 5, 6, and 8A, as well as SMAD4, 6, 7,
and 9. In Fig. 3A, one can see functional connections
known from the literature (i.e. links present in the global
network) for several members of the TGF-beta pathway that
changed their expression upon confrontation, such as
CAMK2A, CDK6, CDKN2B, NR4A1, SMAD3, TGFB1, and
TGFB3.Transcriptional differences associated with tumor cell
inhibition
We measured the degree of PC-3 cell inhibition after 72 h
of in vitro co-culture with the fibroblasts. The fraction of
surviving cells in the pure, non-confronted PC-3 culture
was around 42 %, while in the fibroblast-confronted vari-
ants it ranged from 37.5 % (PdHFB) down to less than
20 % (PrNFB1). The Additional file 1: Figure S2 shows the
averages and 95 % confidence intervals over the replicated
measurements. All the pair-wise differences that we dis-
cuss and use below were significant at p-value <0.0001 by
the Tukey post-hoc test of the one-way ANOVA [29].Comparative analysis of in vitro and ex vivo fibroblasts
First we asked to what extent did the results obtained with
in vitro and ex vivo fibroblasts agree with each other? The
former, being immortalized lines, were more homogenous
and stable. However, it had to be shown that they give re-
sults comparable to the ex vivo material.
Fig. 4 Functional relations of differentially expressed genes with each other and with members of important pathways, as displayed by FunCoup online
resource [14]. a Genes differentially expressed under confrontation with tumor cells and pathway members. Nodes: Yellow, genes of the proinflammatory
signature [27], and/or YAP/TAZ cascade [25], and/or Hippo pathway [26]. Red, confrontation-specific DEGs. Orange: genes that belong to both “yellow”
and “red” categories Line color denotes origin of FunCoup evidence for the network edges (see also “Global interaction network” in Methods): Red,
protein-protein interactions. Blue: co-expression of mRNA. Deep green: links in a KEGG pathway. Multiple lines between the same two nodes indicate that
multiple lines of evidence and were treated as single edges in NEA. Lines with FunCoup confidence <0.1 for the individual component are not shown.
b Genes differently expressed between 4 most and 4 least inhibitory fibroblast cultures before confrontation and pathway members. Yellow: the RhoA
signaling pathway by PID database [30] and pathway for RhoD regulation of cytosceletal dynamics via WHAMM [31]. Red, DEGs between inhibitory and
non-inhibitory fibroblast samples. The the line color, see the legend in A
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ex vivo low-inhibitory counterpart PrTFB2 and compared
them to the highly inhibitory in vitro line Wh1 and its
ex vivo counterpart PrNFB1. By plotting expression fold
change values between the low versus high inhibitory cell
lines before confrontation, we could see a certain similarity
between in vitro and ex vivo cells: the positive correlation
was weak (Spearman rank r = 0.105). After confrontation
even this correlation vanished (r = −0.082) (Additional
file 1: Figure S3).
Similarly to the principal component analysis presented
above, these individual gene values were thus only weakly
informative on the biological process. We therefore de-
cided to investigate the DEGs using NEA. First, we had to
demonstrate that the lists of DEGs between low and high
inhibitory cells collected functionally relevant genes des-
pite the absence of replicates. Assuming that the fold
change values reported true differential expression, we ex-
pected to find functional interrelations between at least a
fraction of the members of DEG lists. This could be
proven with NEA by estimating internal connectivity. In-
deed, we found that the respective DEGs were significantly
interconnected with network links (NEA FDR <10−8 in all
cases). As a negative control, NEA calculated enrichment
for randomly generated gene sets of the same size and
matching network topological properties. Expectedly, noenrichment was found for such sets. For final evidence that
the expression differences between the low and high inhibi-
tory cells in the in vivo and ex vivo pairs were consistent,
we compared network enrichment of DEGs against relevant
pathways. Each such pathway could potentially summarize
a group of related DEGs, so that individual pathway-linked
genes could be regarded as replicates in a statistical analysis
with pathways as factor levels. Unlike the raw gene expres-
sion values, the pathway scores (Fig. 5) were indeed corre-
lated: DEGs from in vitro and ex vivo fibroblasts were
highly associated with the same pathways (Spearman rank
R = 0.686, p0 < 10
−18).
Here again, correlation was only found in the pre-
confrontation transcriptomes, where it increased with
the length of the DEG lists from 30 to 300, i.e. the statis-
tical power grew with the sample size (Additional file 1:
Figure S4a). In other words, gene ranking by fold change
values between in vitro and ex vivo cells could differ,
and the top 300 DEGs were a gene set sufficient to iden-
tify the involvement of all major pathways. The lack of
correlation between confronted transcriptomes was spe-
cifically due to the wiping out of the differences in genes
related to signaling in the in vitro cells after confronta-
tion. Indeed, before confrontation multiple signaling
pathways shaped the differences between the low and
the high inhibitory cells. However after confrontation of
Fig. 5 Pathway scores from network enrichment analysis for DEG lists compiled of genes most differing by mRNA expression level between low and
high inhibitory cell lines in vitro (Wh1 vs. Cr9) and ex vivo (PrNFB1 vs. PrTFB2). The network analysis (see “Network enrichment analysis” in Methods) was
performed on 300 genes with highest fold change between each pair of cell lines. Horizontal and vertical grey lines denote levels of significance in
NEA as false discovery rate = 0.01. Red line displays the linear fit. The text labels are given for pathways with NEA FDR < 0.001 in the both conditions
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those different between low and high inhibitory fibro-
blasts) only reflected basic maintenance processes, such
as cell cycle, RNA-polymerase, protein export, riboso-
mal and proteasomal activities (not shown). Signaling
pathways either received scores close to zero (no enrich-
ment) or even became negative (depletion) (bottom
plots at Additional file 1: Figure S4a). For comparison,
nearly all pathways in the ex vivo lines remained equally
enriched after confrontation (Additional file 1: Figure
S4b). As a possible explanation of this difference, it may
be recalled that the in vitro cells were derived from the
same clone, whereas the ex vivo cells were sampled from
different individuals and were not immortalized, and
therefore prone to senescence, which could decrease
their complexity.
Correlates of the inhibitory capacity
Compared to the confrontation experiment, the identifica-
tion of genes associated with inhibitory capacity was more
difficult. Against the background of dramatic changes
upon the confrontation (the variance due to confrontationwas much higher than that due to differential inhibitory
capacity), it was statistically challenging to evaluate associ-
ation of individual genes with just the inhibitory capacity.
In order to find the inhibition-related features at a more
general, pathway level, we produced DEG lists, each com-
prising 300 genes. Similarly to the described in the previ-
ous section, sets of top 300 genes were sufficient to detect
pathway enrichment. The lists were intended to best dis-
tinguished between high and low inhibitory fibroblasts by
grouping:
 Four of the most inhibitory (in vitro Wh1, and
ex vivo PdSFB, PrNFB1, HS68) vs. four of the least
inhibitory (in vitro Cr9, and ex vivo PdHFB, PrTFB1,
PrTFB2) fibroblast cultures before confrontation and
 the same cultures after confrontation.
While reviewing the NEA results for the list of DEGs
before confrontation (Fig. 2), we noticed that it was sig-
nificantly linked to a range of pathways associated with
cytokine/chemokine functionality and cell-cell interactions
(focal adhesion, adherens junction, gap junction) and to
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lin signaling, JAK-STAT signaling and multiple other path-
ways found in the central area of Fig. 1. A more specific
feature was that the RhoA signaling pathway as presented
in the Pathway Interaction Database [30] and the pathway
for RhoD regulation of cytoskeletal dynamics via WHAMM
[31] were both significantly enriched in network links with
the DEG list. The DEGs most involved in the connection
pattern were interleukin IL6, kinases MAPK8, MAP2K4,
and PRKCA, as well as transcription factors JUN, STAT3,
and STAT5A. A number of transcription factors were asso-
ciated with the DEG list by NEA, such as YBX1, GFI1,
ESR1, ETS1, ETS2, AR, GATA1, GATA2, GATA3 and
PAX2 (although expression of these genes was not altered
significantly). Furthermore, by considering shared binding
sites in promoters and correlation of gene expression, we
established that FOXA1 might be a common regulator of a
number of DEGs, such as annexin ANXA4, kinase CDK6,
kazrin KAZN, the gene RMND5A, “required for meiotic
nuclear division 5 homolog A (S. cerevisiae)”, and tensin
TNS3 (Additional file 1: Figure S1). Most of the pathways
overlapped with those that characterized the response to
confrontation with tumor cells, although details of these
two distinct modes of regulation differed at the level of in-
dividual genes.
Association of the most prominent genes with survival
We used public transcriptomics and clinical data from
The Cancer Genome Atlas (TCGA, 2010) with a two-
fold goal:
1) To validate the relevance of our transcriptomics and
network analyses, and
2) To further investigate potentially relevant properties
of the identified genes and pathways.
The TCGA data were based on samples of primary solid
tumors, with unknown fractions of fibroblasts, which
could vary over a broad range. To what extent were the
samples representative of the fibroblast transcriptomes
and thus tumor cell inhibition that would naturally go on
in vivo? On the one hand, we expected this to be the case
since gene expression had been successfully correlated to
overall survival in the breast carcinoma by Busch et al.
[28] on CAF transcriptomes and by Frings et al. [32] on
complex tumor samples. On the other hand, a study by
Liu et al. [33] reported a direct association between the
size of the stromal fraction and survival in early cervical
carcinoma. We reasoned that in such analyses mRNA ex-
pression would be nearly always affected by extra molecu-
lar factors and spatial cell-to-cell interactions beyond our
control. Therefore in absence of assumptions about spe-
cific biases and by combining analyses from as many as
ten different cancer types, we hoped to reveal associationswith the overall patient survival. If the setup was not ap-
propriate, we could not expect more associated genes than
was expected by chance in a set of randomly picked genes.
For the analysis, we were able to use ten different can-
cers and four high-throughput platforms (two microarray
manufacturers and two RNA-sequencing procedures),
which in total gave 24 cancer/platform combinations. For
technical and biological reasons, these were differently in-
formative on the overall survival. By visually reviewing
genome-wide p-value distributions, we found that each
dataset could report from few to thousands truly corre-
lated genes (i.e. significant after adjustment for multiple
testing). We found significant concordance of genes be-
tween the datasets. Each individual gene received a com-
bined p-value from all these comparisons [34], which was
then in its turn adjusted for multiple testing. This proced-
ure allowed unbiased global (over the 10 cancer types)
ranking for the majority of genes (more than 15,000 by re-
quiring that expression was available from every TCGA
set as well as from our microarray dataset).
We found that a number of DEGs, both from the
confrontation- and inhibition-specific lists, were corre-
lated with relapse-free survival in a number of solid tu-
mors, such as renal and breast carcinoma, as well as
squamous cell carcinomas of head and neck and lung.
However, relevance of our DEG lists to survival could be
proven only if they would be significantly overrepre-
sented, compared to randomly selected genes. First, we
identified enrichment of survival-associated genes for
the “inhibitory vs. non-inhibitory” DEG lists (2.3-fold for
combined p-values <10−6). The comparison involving
only the selected pairs Wh1 vs. Cr9 and PrNFB1 vs.
PrTFB2 yielded even more enrichment (four-fold). For
comparison, the DEG list for the contrast “before vs.
after confrontation” did not show any enrichment (al-
though its network neighbors did, as explained below).
This was a meaningful outcome, as our biological
hypothesis assumed that an active role should belong to
the inhibition.
Importantly, inhibition-related differences between the
in vitro and ex vivo cells again shared similar expression
features. While the lists from each comparison, i.e. DEGs
from Wh1 vs. Cr9 and then separately DEGs from
PrNFB1 vs. PrTFB2, shared 59 genes in total, 11 of the
latter were found to be correlated with survival in TCGA
(combined p-value <0.001), namely EFNB2, TMEM220,
TFAP2C, RPSAP52, SLC40A1, CYP1B1, CHAC1, CCL2,
PSAT1, RCAN2, and SCG2.
The analysis of the DEG list that combined the in vitro
and ex vivo cells (Wh1 vs. Cr9 and PrNFB1 vs. PrTFB2)
identified a number of genes with less obvious roles:
AEBP1 (adipocyte enhancer-binding protein 1), TBC1D1,
previously associated with obesity [35], MXRA8 (limitrin,
matrix-remodelling associated 8), which might be involved
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(plasminogen activator, urokinase receptor), and integrin
ITGA6.
We also considered association with survival for genes
from a collection of 94 pathways that were relevant to sig-
naling in general and to the formation and functioning of
extra-cellular matrix, cell junctions and fibroblast activity
according to current knowledge (Additional file 2: File S1).
Most of these pathways were not associated with survival.
Remarkably however, such pathways as “Rho GTPase
cycle”, “E-cadherin signaling in the nascent adherens
junction”, “Adherens junction”, as well as GO term “Rho
GTPase activator activity”, were enriched in survival-
associated genes from 2- to 4-fold. In addition, 3 out of our
12 in silico CAF markers [7], 12 genes of the pro-
inflammatory CAF signature [27], 16 genes of the Hippo
pathway [26], and 3 genes of the YAP/TAZ pathway [25]
were found in the overrepresented sets. Next, we investi-
gated if network neighbors of the members of our DEG
lists were enriched among the survival-associated genes
(Additional file 2: File S1). Such gene groups were often
even more overrepresented than DEGs and pathway mem-
bers by themselves, up to 7–8 folds. A similar network ana-
lysis identified network neighbors of the pathways
mentioned above, which again increased the number and
significance of the overlap. The full list of DEGs and path-
way members associated survival can be found in the Add-
itional file 2: File S1.
Based on our analysis we propose that the group of
genes discovered via network enrichment against survival
genes (both individually and as a whole group) should be
subjected to further investigation by the combination of
our methods (Table 1).
Discussion
We confronted fibroblasts with cancer cells and inter-
preted transcriptomes of the former, before and after the
confrontation, using statistical and systems biology proce-
dures. Against the background of histological, clinical, and
genetic differences between the fibroblasts, we gained in-
sights into the biological processes in question using a
self-controlled, differential experimental design.
The network enrichment analysis that we applied com-
bined effects of both up- and down-regulated genes. This
allowed summarizing features to the pathway level. When
enrichment of a certain pathway was significant for differ-
ent DEG lists (e.g. those that characterized confrontation
and inhibition), individual DEGs behind the enrichments
might still vary. In other words, the algorithm of NEA
allowed identifying same pathways via different, condition-
specific gene sets, which might partially overlap with each
other. This increased the sensitivity of the analysis and the
generality of the conclusions, but posed an extra challenge
for the interpretation. Which individual genes should bepicked up for experimental validation? Since our study was
based on transcriptome analysis, we focused on potential
regulators of transcription. We started from an exploratory
analysis at the level of whole pathways, and demonstrated
that individually insignificant genes can produce a network
connectivity pattern that was extremely unlikely to occur in
a random set of genes. For comparison, the traditional gene
set enrichment analysis [21] was much less efficient on the
same DEG lists, because only very few DEGs were direct
members of respective pathways. Many relations between
individual transcription factors and DEGs were further con-
firmed by gene expression analysis.
We found that many functional links between a TF and
a downstream gene could be confirmed by gene expres-
sion correlation. However, even when such correlation
could not be identified, functional relations were still
likely, since an up-stream TF might be constitutively
expressed and regulated, e.g. by physical protein interac-
tions or co-binding with other TFs.
Cells from different original sources served as biological
replicates in this experimental design. Despite the poten-
tial pitfalls of this setting, such as loss of statistical power
(many false negatives) and spurious positive results due to
excessive biological variability, we likely captured the
general features that could be recurrently reproduced in
future research. This was helped by our self-controlled
paired analysis design where pre-confrontation and post-
confrontation data of the same cell line were directly com-
pared. Importantly, NEA was indispensable here as well,
due to its ability to integrate results both at the individual
pathway and signaling network levels. Using NEA, we
could confirm the validity of DEG lists in two ways: 1) by
detecting the internal coherence of the lists, i.e. significant
enrichment of connections (network edges) within the list
compared to a pattern expected in a random gene list, and
2) by observing multiple pathways significantly enriched
in relations to the DEG genes compared to the number of
similarly enriched pathways for a random gene list.
Our use of cell lines as biological replicates was similar
to the approach of high-throughput profiling in large
cancer projects. It is usually done on either unique pri-
mary tumor samples or cancer cell lines of very different
origin (an example can be found in the analysis of pri-
mary tumors versus metastasis sites of ovarian tumor by
Malek et al. [37]), which permits the evaluation of ran-
dom effects of biological samples, i.e. biological variation
in general rather than features of specific phenotypes.
We note that the range of cells that could potentially
interact with tumor ones is not even limited to fibro-
blasts and includes e.g. prostate adipocytes [38].
We also addressed the problem of contamination of
post-confrontation fibroblasts with cancer cells and the
potential bias in the transcriptome measurements in the
confronted cultures. The overall signal was strong and
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the non-contaminated samples. Bias in the analysis of in-
hibition could be ruled out by common features between
Wh1 versus Cr9 (both contaminated) on the one hand
and PrNFB1 versus PrTFB2 (both uncontaminated) sam-
ples. In parallel, the principal component analysis (Fig. 1)
did not indicate any specifically strong fraction of variabil-
ity due to the presence of cancer cells. We reported only
genes reproduced in the both comparisons.
The changes due to confrontation were much more dras-
tic than those associated with differences in inhibitory cap-
acity, which warranted different approaches to the analysis
and the statistical validation. At the same time, the two
types of analyses highlighted an overlap between the indi-
vidual genes, signaling systems and processes, although with
different functional implications. We detected association of
our DEGs with cell-cell interaction (in the form of focal ad-
hesion, adherens junction, and gap junction pathways) and
signaling systems that should be involved in the confronta-
tion process according to previous research, such as Rho
signaling [7, 31] YAP/TAZ cascade [25], the proteins of the
pro-inflammatory signature [27], and biomarkers of CAF-
ness [7]. Among pathways and biological processes associ-
ated with differential inhibitory capacity were, again, those
responsible for cell-cell interactions, the RhoD pathway
[31], and the pro-inflammatory signature [27].
The set of genes that we discussed and prioritized in
this work are summarized in Table 1. The general rule
for inclusion into this table was the potential to have a
broader impact on either the confrontational response
or the inhibitory capacity and thus to allow reexamining,
in future experiments, the effects observed in the
present confrontation assay.
Using this gene list, we and others would be able to con-
nect the global, pathway-level view on the interaction be-
tween fibroblasts and cancer cells with gene-focused
approaches of experimental research and eventual devel-
opment of novel anti-cancer drugs.Additional files
Additional file 1: Figure S1. Correlation patterns of transcription
factors and their potential targets identified in the network analysis.
Figure S2. Inhibition scores as fraction of survived PC-3 cells after 72 h
co-cultivation with fibroblasts. The technique is described by Alkasalias
et al. [8]. Figure S3. Comparison of differential expression using raw gene
expression values between low and high inhibitory cell lines in vitro (fold
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